发明名称 |
COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXITY (ADCC) |
摘要 |
The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine. |
申请公布号 |
US2014065134(A1) |
申请公布日期 |
2014.03.06 |
申请号 |
US201313829409 |
申请日期 |
2013.03.14 |
申请人 |
ROCHE GLYCART AG |
发明人 |
DUMONTET CHARLES;FRIESS THOMAS;HERTING FRANK;KLEIN CHRISTIAN;UMANA PABLO |
分类号 |
A61K39/395;A61K31/475;A61K31/573;A61K31/675;A61K31/704 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|